• ETR and RAL were studied in similar patient populations, and have similar indications to treat HIV-1-infected adult patients in the USA • Based on the results showing similar efficacy rates in reaching the treatment goal of <50 copies/mL, a costminimisation approach can be taken when evaluating the addition of ETR or RAL to a HAART regimen for treatmentexperienced patients
• Applying the cost-minimisation approach, ETR costs US$2,478 less than RAL to add to a regimen for treatmentexperienced HIV patients • This analysis does not account for additional savings in hospitalisations 9 or reductions in AIDS-defining illnesses and deaths 10 that have been shown to be associated with ETR
Abstract
HIV treatment guidelines state that the goal of highly active antiretroviral therapy (HAART) is to achieve an undetectable viral load (<50 copies/mL) in HIV-infected patients. Two new therapies, etravirine (ETR; TMC125) and raltegravir (RAL), have recently been approved in the USA, both with similar indications for treatment-experienced HIV-1-infected patients. This analysis compared the relative cost of reaching this treatment goal for each therapy. Both ETR and RAL showed similar efficacy rates in achieving undetectable viral load. As a result, a cost-minimisation approach can be taken when evaluating the addition of ETR or RAL to a HAART regimen for treatment-experienced HIV-1infected patients.
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